Replies to post #41890 on Innovation Pharmaceuticals Inc (IPIX)

[MrW]

Speaking of that other than Aspire, what big money is in this right now? While you're chastising us peons we're still the only ones in it!

[BonelessCat]

Agree. And, what I said a week ago is proving out:

Sept 10: Pursuing the antibiotic because it is ready for advanced trials in a Phase 2b. It's a no brainer. It's so much a no brainer I can't figure out what all the angst is about. From what I've put together it's nothing more than pay the clinical sites and start recruiting for the next phase trial. Polymedix ran out of money preparing for the Phase 2b. No brainer here. Takes no brains at all.

Sept 11: Phase 2b primary outcome is optimal dosing. Safety and efficacy is already established at both high and low doses.

No brainer here. Complete 2b, take partner and $40 million upfront, and if Phase 3 does fail CTIX still has $35 million return on $2 million cash payment for B. No brainer.

Sept 11: Everything points to B being ready for the next Phase 2b. Everything.

Occam's Razor, PolyMedix simply fell under the radar of other biopharmas.

Sept 12: According to the B profile, due to its MOA, resistance to the drug is unlikely. Yet another benefit over current antibiotics.

Sept 12: Polymedix investors didn't react negatively to the clinical outcomes; the reacted negatively to the financial events at the time of the Phase 2 completion and data release. The SP was cratering due to heavy dilution following security based financing and toxic financing structures. At the same time the company reverse split the shares, they announced not one but two share-based funding rounds for $24 million. That's right, a company reverse split and immediately filed two prospectus for separate offerings. It was like management was determined to fail.

Not only did that chill investors to PolyMedix, but Big Parmas interested in partnering couldn't get enough distance. Those Big Pharmas are the same that Leo mentioned in his talk with whom he has already been in contact.

Yes, the drug may ultimately fail in expanded Phase 3, but after a Phase 2b that includes dose optimization, a license or partner should be there for a drug less valuable than Prurisol or Kevetrin. Again, from what I see so far, PolyMedix did nearly all the prelimibnary work toward the 2b study.

OK, that's enough.

I don't profess to be a financial genius but I don't think investors realize the genius behind what Leo has done to date with all the trials going on (gratis) and the Pymx aq.as well as the rest of the financing deals that have cost US NOTHING to Date.

People need to give credit where credit is due (and be grateful) and realize that they are investors and not the movers and shakers here.

Kelt